Emergent TRU-016 granted #OrphanDrug designation by FDA

In Uncategorized by Caroline Hornby

fda orphan drug designation The FDA has granted Emergent BioSolutions orphan drug designation for TRU-016 protein therapeutic.

Read the full article here.

The therapeutic is for the treatment of chronic lymphocytic leukemia. "Emergent is pleased to receive this designation and is committed to advancing product candidates that improve the lives of patients suffering from diseases like CLL," chief medical officer Scott Stromatt stated.

For up to date industry news on orphan drugs and rare diseases, check out the World Orphan Drug Congress USA.